| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
An Evidence-Based Rationale for Dose De-escalation of Subcutaneous Atezolizumab
|
Kicken, Mart P.
|
|
|
19 |
5 |
p. 779-787
|
artikel
|
| 2 |
A Phase 1a/1b Dose Escalation/Expansion Study of the Anti-PD-1 Monoclonal Antibody Nofazinlimab in Chinese Patients with Solid Tumors or Lymphoma
|
Gong, Jifang
|
|
|
19 |
5 |
p. 723-733
|
artikel
|
| 3 |
Author’s Reply to Ma et al.: “Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis”
|
Maiorano, Brigida Anna
|
|
|
19 |
5 |
p. 813-815
|
artikel
|
| 4 |
Comment on: “Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta‑analysis”
|
Ma, Jun
|
|
|
19 |
5 |
p. 811-812
|
artikel
|
| 5 |
Correction to: Moving T‑Cell Therapies into the Standard of Care for Patients with Relapsed or Refractory Follicular Lymphoma: A Review
|
Fowler, Nathan Hale
|
|
|
19 |
5 |
p. 817
|
artikel
|
| 6 |
Current State of Targeted Therapy in Adult Langerhans Cell Histiocytosis and Erdheim–Chester Disease
|
Lin, He
|
|
|
19 |
5 |
p. 691-703
|
artikel
|
| 7 |
Efficacy and Safety of Durvalumab/Tremelimumab in Unresectable Hepatocellular Carcinoma as Immune Checkpoint Inhibitor Rechallenge Following Atezolizumab/Bevacizumab Treatment
|
Sho, Takuya
|
|
|
19 |
5 |
p. 769-778
|
artikel
|
| 8 |
Identifying Actionable Alterations in KRAS Wild-Type Pancreatic Cancer
|
Elhariri, Ahmed
|
|
|
19 |
5 |
p. 679-689
|
artikel
|
| 9 |
lnsights into Adjuvant Systemic Treatment Selection for Patients with Stage III Melanoma: Data from the Dutch Cancer Registry
|
Aldenhoven, Loeki
|
|
|
19 |
5 |
p. 735-745
|
artikel
|
| 10 |
Malignant Peripheral Nerve Sheath Tumor, a Heterogeneous, Aggressive Cancer with Diverse Biomarkers and No Targeted Standard of Care: Review of the Literature and Ongoing Investigational Agents
|
Somaiah, Neeta
|
|
|
19 |
5 |
p. 665-678
|
artikel
|
| 11 |
Model-Informed Development of a Cost-Saving Dosing Regimen for Sacituzumab Govitecan
|
Moes, Dirk J. A. R.
|
|
|
19 |
5 |
p. 789-796
|
artikel
|
| 12 |
Patient Enrollment per Month (Accrual) in Clinical Trials Leading to the FDA Approval of New Cancer Drugs
|
Michaeli, Daniel Tobias
|
|
|
19 |
5 |
p. 797-809
|
artikel
|
| 13 |
Pembrolizumab in Patients with Advanced Urothelial Carcinoma with ECOG Performance Status 2: A Real-World Study from the ARON-2 Project
|
Rizzo, Alessandro
|
|
|
19 |
5 |
p. 747-755
|
artikel
|
| 14 |
Risk Stratification According to Baseline and Early Change in Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Treated with Chemoimmunotherapy: A Multicenter Real-World Study
|
Matsumoto, Kinnosuke
|
|
|
19 |
5 |
p. 757-767
|
artikel
|
| 15 |
Safety and Preliminary Efficacy of Once-Weekly Split-Dose Selinexor in Soft Tissue Sarcoma: Results of the Phase Ib METSSAR Clinical Trial
|
Salawu, Abdulazeez
|
|
|
19 |
5 |
p. 711-721
|
artikel
|
| 16 |
Trastuzumab-Deruxtecan: Redefining HER2 as a Tumor Agnostic Biomarker
|
Zouein, Joseph
|
|
|
19 |
5 |
p. 705-710
|
artikel
|
Tijdschrift beschrijving